Insurer, Insured Costs for HIV PrEP Rising in the United States
WEDNESDAY, Sept. 9, 2020 -- From 2014 to 2018, there were increases noted in third-party and out-of-pocket (OOP) payments per 30 tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) tablets for HIV preexposure prophylaxis (PrEP), according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 9, 2020 Category: Pharmaceuticals Source Type: news

' Vacation PrEP': Short-Term HIV Prevention a Viable Option
THURSDAY, Aug. 27, 2020 -- The daily use of antiretroviral meds to help prevent HIV infection has been around for a few years now -- it's called pre-exposure prophylaxis, or PrEP. PrEP includes combo drugs such as Truvada (tenofovir/emtricitabine).... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 27, 2020 Category: General Medicine Source Type: news

GSK Says Long-Acting HIV Prevention Drug 65% More Effective Than Truvada GSK Says Long-Acting HIV Prevention Drug 65% More Effective Than Truvada
Britain's GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 65% more effective in preventing HIV infections than Gilead's Truvada daily oral pills.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 8, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

A Shot to Protect Against H.I.V.
A drug injected every two months is more effective at preventing H.I.V. infection than a daily pill, scientists report. (Source: NYT Health)
Source: NYT Health - July 7, 2020 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Drugs (Pharmaceuticals) Women and Girls Transgender and Transsexuals Clinical Trials Gilead Sciences Inc Viiv Healthcare Ltd Brazil your-feed-science Source Type: news

Brazilian AIDS Patient Shows No Sign of Virus After Experimental Drug Therapy
A Brazilian man infected with the AIDS virus has shown no sign of it for more than a year since he stopped HIV medicines after an intense experimental drug therapy aimed at purging hidden, dormant virus from his body, doctors reported Tuesday. The case needs independent verification and it’s way too soon to speculate about a possible cure, scientists cautioned. “These are exciting findings but they’re very preliminary,” said Dr. Monica Gandhi, an AIDS specialist at the University of California, San Francisco. “This has happened to one person, and one person only,” and it didn’t suc...
Source: TIME: Health - July 7, 2020 Category: Consumer Health News Authors: Marilynn Marchione / AP Tags: Uncategorized HIV/AIDS News Desk wire Source Type: news

Long-acting injectable form of HIV prevention outperforms daily pill in NIH study
(NIH/National Institute of Allergy and Infectious Diseases) A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by NIH. Findings from the Phase 2b/3 study, called HPTN 083, will be discussed during the 23rd International AIDS Conference (AIDS 2020: Virtual). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 7, 2020 Category: Infectious Diseases Source Type: news

HPTN 083 study demonstrates superiority of cabotegravir for the prevention of HIV
(FHI360) The HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 7, 2020 Category: Infectious Diseases Source Type: news

GSK's Long-Acting Injection Beats Truvada in HIV Prevention Trial GSK's Long-Acting Injection Beats Truvada in HIV Prevention Trial
GSK said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead's daily Truvada pill.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 19, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

GSK's long-acting injection beats Truvada in HIV prevention trial
GlaxoSmithKline said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead's daily Truvada pill, potentially giving its ViiV unit a foothold in HIV prevention. (Source: Reuters: Health)
Source: Reuters: Health - May 18, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Title: Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/17/2020 12:00:00 AMLast Editorial Review: 4/17/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 17, 2020 Category: Infectious Diseases Source Type: news

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)
Title: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/16/2020 12:00:00 AMLast Editorial Review: 4/16/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 16, 2020 Category: Infectious Diseases Source Type: news

Sex and the Coronavirus: Reader Questions, Answered
Will there be a baby boom in nine months? Is this a bad time to get pregnant? Could PrEP protect me? And should high-risk people abstain altogether? (Source: NYT Health)
Source: NYT Health - April 10, 2020 Category: Consumer Health News Authors: Jen Gunter Tags: Coronavirus (2019-nCoV) Pregnancy and Childbirth Birth Rates Sex Truvada (Drug) Source Type: news

Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
Anecdotal, unsubstantiated reports claim that darunavir has antiviral effect against COVID-19Johnson & Johnson has no evidence that darunavir has any effect against SARS-CoV-2, the virus that causes COVID-19Johnson & Johnson is screening its antiviral compounds, including darunavir, to determine potential in vitro effect against SARS-CoV-2We are partnering with multiple organizations to support the development of research programs and fast-track solutions for COVID-19Considering the large public health and humanitarian implications, we are committed to global efforts to care for those affected, contain the current ...
Source: Johnson and Johnson - March 16, 2020 Category: Pharmaceuticals Tags: Corporate Source Type: news

New HIV PrEP Drug Not Cost-Effective Compared With Generic
WEDNESDAY, March 11, 2020 -- Use of tenofovir alafenamide-emtricitabine (F/TAF) is not cost-effective compared with generic tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) among men who have sex with men... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2020 Category: Pharmaceuticals Source Type: news

Newer anti-HIV drugs safest, most effective during pregnancy
(NIH/National Institute of Allergy and Infectious Diseases) The antiretroviral drugs dolutegravir and emtricitabine/tenofovir alafenamide fumarate (DTG+FTC/TAF) may comprise the safest and most effective HIV treatment regimen currently available during pregnancy, researchers announced today. Their findings come from a multinational study of more than 640 pregnant women with HIV across four continents. The current study compared three antiretroviral drug regimens and found that regimens containing dolutegravir (DTG) were more effective in suppressing HIV than a commonly used regimen containing efavirenz (EFV). (Source: Eure...
Source: EurekAlert! - Medicine and Health - March 11, 2020 Category: International Medicine & Public Health Source Type: news

Cardiovascular Safety Signal for Descovy in HIV PrEP Cardiovascular Safety Signal for Descovy in HIV PrEP
Final DISCOVER data might provide some answers on the higher rate of statin use in patients on Descovy, but a growing number of experts are urging clinicians to stick with Truvada.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 7, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Uptick in Statin Use After Descovy in HIV PrEP Uptick in Statin Use After Descovy in HIV PrEP
Final DISCOVER data might provide some answers on the higher rate of statin use in patients on Descovy, but a growing number of experts are urging clinicians to stick with Truvada.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 6, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Emtricitabine/tenofovir alafenamide not cost effective despite fewer AEs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2020 Category: Drugs & Pharmacology Source Type: news

D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for treating newly diagnosed HIV-1 infection before baseline laboratory results are available, according to results from the DIAMOND phase-3 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 21, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Truvada should remain first choice for HIV prevention, experts say
(Harvard Pilgrim Health Care Institute) In October 2019, the FDA approved a second medication for use as HIV preexposure prophylaxis, also known as PrEP, sparking controversy about which drug should be prescribed. Gilead Sciences, which manufactures both approved drugs, has argued that the new drug is safer and more effective than the old drug. But these claims are overstated, say a team of clinical and public health experts. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 13, 2020 Category: Infectious Diseases Source Type: news

Four-Drug Combination Effective Long-Term for HIV Suppression Four-Drug Combination Effective Long-Term for HIV Suppression
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for long-term viral suppression in previously untreated patients with HIV-1 infection, according to 96-week results from the AMBER trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Facebook Asked to Remove'Factually Inaccurate' Ads About PrEP
THURSDAY, Dec. 12, 2019 -- Facebook should remove " factually inaccurate " ads that " suggest negative health effects " of the HIV-prevention medication Truvada, more than 50 LGBTQ, HIV, and public health groups say in an open letter to the company. The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2019 Category: Pharmaceuticals Source Type: news

Activists and LGBTQ Groups Say These Facebook Ads Spread Dangerous Misinformation About HIV Drugs
Advocacy groups are urging Facebook to remove advertisements that they say unfairly infer that the HIV/AIDS prevention Truvada PrEP (pre-exposure prophylaxis) is dangerous, an allegation they say could endanger the people who are most at risk of contracting the disease. More than 50 HIV/AIDs, LGBTQ and public health advocacy groups released a letter on Monday asking Facebook and Instagram to remove the ads from their platforms. The ads referred specifically to “Truvada PrEP” (the brand name for one of the medications, dtenofovir disoproxil fumarate, used as PrEP) and in some cases more generically to “PrE...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized health LGBTQ onetime Source Type: news

200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs
A new government program will provide donated drugs through major drugstore chains. (Source: NYT Health)
Source: NYT Health - December 3, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome PrEP (Pre-exposure prophylaxis for H.I.V.) Truvada (Drug) Gilead Sciences Inc Health and Human Services Department Azar, Alex M II Drugs (Pharmaceuticals) Tests (Medical) Health Insurance and Managed Car Source Type: news

200,000 People Without Insurance May Apply for Free H.I.V.-Prevention Drugs
A new government program will provide donated drugs through major drugstore chains. (Source: NYT Health)
Source: NYT Health - December 3, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome PrEP (Pre-exposure prophylaxis for H.I.V.) Truvada (Drug) Gilead Sciences Inc Health and Human Services Department Azar, Alex M II Drugs (Pharmaceuticals) Tests (Medical) Health Insurance and Managed Car Source Type: news

Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says
In an unexpected lawsuit, federal officials claim that Gilead Sciences willfully disregarded government patents on medicines necessary to end the AIDS epidemic. (Source: NYT Health)
Source: NYT Health - November 8, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. and Apoorva Mandavilli Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Inventions and Patents Drugs (Pharmaceuticals) Royalties Health and Human Services Department National Institutes of Health Azar, Alex M II Cummings, Elijah E Stabenow, Debbie Source Type: news

Trump Administration Sues Gilead, Maker of H.I.V.-Prevention Drugs
The lawsuit accused the pharmaceutical company of profiting billions of dollars off taxpayer research without paying royalties. (Source: NYT Health)
Source: NYT Health - November 7, 2019 Category: Consumer Health News Authors: Daniel Victor Tags: Gilead Sciences Inc Truvada (Drug) Health and Human Services Department Inventions and Patents Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Source Type: news

California Makes H.I.V.-Prevention Drugs Available Without a Prescription
The state is the first in the nation to allow pharmacists to dispense PrEP and PEP, drugs that can prevent new H.I.V. infections. (Source: NYT Health)
Source: NYT Health - October 9, 2019 Category: Consumer Health News Authors: Karen Zraick and Sandra E. Garcia Tags: Drugs (Pharmaceuticals) Truvada (Drug) Acquired Immune Deficiency Syndrome Drug Resistance (Microbial) Drugstores Equality California Newsom, Gavin Source Type: news

F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Everyone
Citing a lack of evidence, the agency will require Gilead to conduct additional trials in individuals ‘who have receptive vaginal sex.’ (Source: NYT Health)
Source: NYT Health - October 8, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news

F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Cisgender Women
Citing a lack of evidence, the agency will require Gilead to conduct additional trials. (Source: NYT Health)
Source: NYT Health - October 8, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news

F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Women
Citing a lack of evidence, the agency will require Gilead to conduct further trials in women. (Source: NYT Health)
Source: NYT Health - October 4, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) indication for Descovy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 4, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Descovy, Second Drug for HIV PrEP FDA OKs Descovy, Second Drug for HIV PrEP
The combo of emtricitabine and tenofovir alafenamide is indicated to reduce the risk for HIV-1 infection from sex (excluding receptive vaginal sex) in at-risk adults and teens weighing at least 35 kg.FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 3, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Source: World Pharma News)
Source: World Pharma News - October 3, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Gilead to challenge US patents on HIV drug Truvada
Move comes amid increasing scrutiny of drugmaker over pricing practices (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 21, 2019 Category: Pharmaceuticals Source Type: news

Gilead did not seek US exclusivity on PrEP with Truvada
Drugmaker could be liable for billions in royalties to US government (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 18, 2019 Category: Pharmaceuticals Source Type: news

Would You Want a Computer to Judge Your Risk of H.I.V. Infection?
A new software algorithm decides which patients are most likely to become infected with the virus. But this is not like other risk calculators, some experts say. (Source: NYT Health)
Source: NYT Health - July 30, 2019 Category: Consumer Health News Authors: Gina Kolata Tags: Tests (Medical) Truvada (Drug) Acquired Immune Deficiency Syndrome Electronic Health Records Computers and the Internet Homosexuality and Bisexuality Sexually Transmitted Diseases Harvard University Kaiser Permanente United States Source Type: news

Most High-Risk Men Don ’t Take PrEP to Prevent H.I.V.
In a survey, only about one in three American men who were at high risk for H.I.V. infection took Truvada to prevent transmission. (Source: NYT Health)
Source: NYT Health - July 25, 2019 Category: Consumer Health News Authors: Toby Bilanow Tags: Truvada (Drug) Acquired Immune Deficiency Syndrome Sexually Transmitted Diseases Blacks Condoms Hispanic-Americans Source Type: news

Someday, an Arm Implant May Prevent H.I.V. Infection for a Year
In preliminary tests, a matchstick-size rod containing a new drug offered promise as a shield against the virus. But a large clinical trial must still be done. (Source: NYT Health)
Source: NYT Health - July 23, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Inventions and Patents Implants Merck & Company Inc National Institute for Allergy and Infectious Disease (NIAID) Fauci, Anthony S Africa Source Type: news

PrEP use high but wanes after three months among young African women
(NIH/National Institute of Allergy and Infectious Diseases) In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among young African women and adolescent girls, 95% initiated PrEP, and most used PrEP for the first three months. However, PrEP use fell in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored strategies may be needed to engage young African women in consistent PrEP use. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 23, 2019 Category: Infectious Diseases Source Type: news

Lower than expected risk of bone density decline with Truvada PrEP
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use -- very high adherence -- had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2019 Category: International Medicine & Public Health Source Type: news

How Australia Could Almost Eradicate H.I.V. Transmissions
The most recent advance in Australia ’s decades-long fight against the virus is the rapid adoption of a preventive drug regimen known as PrEP. (Source: NYT Health)
Source: NYT Health - July 11, 2019 Category: Consumer Health News Authors: Livia Albeck-Ripka Tags: Truvada (Drug) Acquired Immune Deficiency Syndrome Health Insurance and Managed Care Homosexuality and Bisexuality Australia United States Source Type: news

Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2019 Category: Drugs & Pharmacology Source Type: news

FDA In Brief: FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV
Because patients and doctors understand the risks of using Truvada for PrEP, and educational materials are available from CDC, FDA eliminated the REMS for Truvada and its generics. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 2, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

UCLA Health to launch fellowship focused on LGBTQ care
To help ensure that future primary care doctors are able to address the physical and mental health care needs of people who are LGBTQ, UCLA Health has created an immersive, one-year fellowship focused on LGBTQ-centered care.TheUCLA LGBTQ Fellowship, which starts on July 1, was conceived about a year ago by faculty in the internal medicine department at theDavid Geffen School of Medicine at UCLA to address LGBTQ-specific topics, which often are not adequately addressed in medical school and residency training.The training will help doctors provide the best counsel for disease prevention and screening, sexual and behavioral ...
Source: UCLA Newsroom: Health Sciences - June 22, 2019 Category: Universities & Medical Training Source Type: news

Expert Panel Backs PrEP for People at High HIV Risk
Best known as the two-drug combo pill Truvada, PrEP prevents HIV from establishing a permanent infection in people exposed through sex or injection drug use, the CDC says. (Source: WebMD Health)
Source: WebMD Health - June 11, 2019 Category: Consumer Health News Source Type: news

For the First Time, an Expert Panel Is Recommending a Drug to Prevent High-Risk Groups From Getting HIV
Over the past few decades, doctors and researchers have made admirable progress in controlling the spread of HIV, mainly by using anti-HIV drugs in powerful combinations that can make it harder for the virus to infect cells and pump out more copies of itself. But as any infectious-disease expert knows, preventing new infections is equally as important as treating existing cases to contain an epidemic. And in the U.S. each year, nearly 40,000 people are still newly diagnosed with HIV. With its latest recommendation, published in JAMA, the U.S. Preventive Services Task Force (USPSTF) issued its strongest strategy yet for pre...
Source: TIME: Health - June 11, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV hiv prevention Infectious Disease Source Type: news

U.S. Expert Panel Supports HIV-Prevention Pill Truvada, for People at High Risk
TUESDAY, June 11, 2019 -- A daily pill that can block transmission of HIV should be prescribed to people at high risk of infection with the AIDS-causing virus, according to a highly influential panel of experts. The treatment -- called pre-exposure... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2019 Category: General Medicine Source Type: news

Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment
A single-tablet regimen of bictegravir, emtricitabine and tenofovir alafenamide is noninferior to regimens of dolutegravir coformulated with emtricitabine and tenofovir alafenamide or with abacavir and lamivudine for the initial treatment of HIV-1 infection, according to results from two randomized phase 3 trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 7, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Health activists fighting to lower cost of a revolutionary HIV drug
The organization PrEP4All is facing off with a major pharmaceutical company over the growing price of Truvada, a revolutionary HIV drug. A 30-day supply of Truvada costs around $1,700. No cheaper version of the same drug is available in the United States. Health advocate Emily Sanderson joins CBSN to disucss. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 5, 2019 Category: Consumer Health News Source Type: news